Bladder Cancer,Genitourinary Cancer Safety and Efficacy of sEphB4-HSA+Pembrolizumab in Patients with Solid Tumors: Phase 2 Trial Apr 20, 2023
Bladder Cancer,Genitourinary Cancer EV for the Treatment of LA/mUC Bladder Cancer: EV-201 in Phase 2 Trial Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Evaluating the Efficacy of Cabozantinib and Avelumab in Metastatic Urothelial Cancer: MAIN-CAV in Phase 3 Trial Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Neoadjuvant Atezolizumab in MIBC Patients Ineligible for Cisplatin: ABACUS in Phase 2 Trial Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Phase 2 BAYOU Trial: Investigating the Efficacy of Durvalumab and Olaparib in Platinum-Ineligible Bladder Cancer Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Phase 2 RACE IT Study: Revolutionizing Treatment for Urothelial Carcinoma Patients Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Neoadjuvant Pembrolizumab in MIBC: PURE-01 Follow Up Trial Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Enfortumab Vedotin vs. Standard Chemotherapy for Advanced Urothelial Cancer: Phase 3 Results from EV-301 Apr 20, 2023
